A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorDaiichi Sankyo
About this trial
This clinical trial is designed to assess the safety, preliminary efficacy, and pharmacokinetics (PK) of DS3790a monotherapy and combination regimens in participants with hematological malignancies.
Eligibility criteria
Qualifiers
Sign and date the ICF, prior to the start of any trial-specific procedures.
Adults >=18 years at the time the ICF is signed.
History of one of the histologically documented hematologic malignancies according to the 5th edition of WHO classification as specified in the protocol.
NHL participants only: Agree to provide baseline tumor tissue samples as specified in the protocol.
Disqualifiers
None
Trial design
Treatments tested in this trial
- DS3790a
- Combination drug
- Combination drug
Treatment groups
420 Participants
are divided into 8 treatment groups8
Treatment groupsSee each treatment group below.
Locations
5France
Research Site59037, Lille France
Japan
Research Site464-8681, Nagoya Japan
Research Site104-0045, Tokyo Japan
Research Site135-8550, Tokyo Japan
Sponsors and collaborators
Daiichi Sankyo
Lead sponsor
Source ClinicalTrials.gov